Welcome to our dedicated page for Rani Therapeutics Holdings SEC filings (Ticker: RANI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rani Therapeutics Holdings, Inc. filings document the regulatory record of a clinical-stage biotherapeutics company developing oral delivery technology for biologics and drugs. Form 8-K reports include quarterly and annual financial results, corporate updates, clinical and preclinical program disclosures, collaboration and license matters, and material agreements affecting the company’s operations and strategy.
The filing record also covers capital-structure activity involving Class A common stock, common warrants and pre-funded warrants, as well as Nasdaq continued-listing compliance notices. Proxy materials describe annual meeting matters, board elections, auditor ratification, governance procedures and stockholder voting mechanics for RANI’s public-company structure.
Rani Therapeutics Holdings, Inc. reported that Chief Business Officer Kate McKinley received a grant of stock options covering 805,500 shares of Class A Common Stock. The options have an exercise price of $0.875 per share and expire on June 2, 2036.
According to the grant terms, one forty-eighth of the options vest monthly over four years starting April 1, 2026, as long as she maintains continuous service with the company. Following this award, she holds 805,500 stock options, aligning a portion of her compensation with the company’s future share performance.
Rani Therapeutics Holdings, Inc. reported that Chief Technical Officer Alireza Javadi received a grant of stock options covering 805,500 shares of Class A common stock. The options have an exercise price of $0.875 per share and expire on June 2, 2036.
According to the grant terms, 1/48th of the options vest monthly over four years starting April 1, 2026, as long as he maintains continuous service with the company. This is a compensation-related award, not an open-market purchase or sale.
Rani Therapeutics Holdings, Inc. reported that Chief Executive Officer Imran Talat received a grant of stock options covering 3,800,000 shares of Class A Common Stock. The options have an exercise price of $0.875 per share and expire on June 2, 2036.
According to the award’s terms, 1/48th of the underlying shares vest monthly over four years starting April 1, 2026, conditioned on his continued service with the company. Following this grant, Talat holds stock options on 3,800,000 shares directly, with no open-market buys or sells reported in this filing.
Rani Therapeutics Holdings director Abraham Bassan received a grant of 123,600 stock options for Class A Common Stock. The options were awarded at an exercise price of $0.9515 per share and represent his entire reported derivative holdings after this transaction.
The option grant vests in full on the first anniversary of the grant date, subject to his continued service. Vesting may occur earlier if the company holds its next annual stockholder meeting or if a Change in Control occurs, provided he maintains Continuous Service through that date.
Rani Therapeutics Holdings director Lisa Ann Rometty received a stock option grant covering 123,600 shares of Class A common stock. The option has an exercise price of $0.9515 per share and expires on May 27, 2036.
The option vests in full on the first anniversary of the May 28, 2026 grant date, subject to her Continuous Service under the company’s 2021 Equity Incentive Plan. Vesting may occur earlier if either the company’s next annual stockholder meeting or a Change in Control occurs while she continues in service. Following this grant, she holds 123,600 option shares directly.
Rani Therapeutics Holdings, Inc. director and ten percent owner Imran Mir A received a grant of options to acquire 123,600 shares of Class A Common Stock. The options have an exercise price of 0.9515 per share and expire on May 27, 2036.
These director stock options vest in full on the first anniversary of the grant date, subject to continuous service, or earlier upon the company’s next annual stockholder meeting or a Change in Control, also subject to continuous service. Following this grant, the filing shows 123,600 derivative securities held directly.
Rani Therapeutics Holdings director Jean Luc Butel received a grant of stock options covering 123,600 shares of Class A common stock. The options have an exercise price of $0.9515 per share and expire on May 27, 2036.
The options were awarded as compensation, not purchased in the open market. According to the award terms, the options vest in full on the first anniversary of the May 28, 2026 grant date, provided the director maintains Continuous Service. They may vest earlier if the company holds its next annual stockholder meeting or undergoes a Change in Control while the director remains in service.
Rani Therapeutics director Bailey Vasudev Jaiprakash received a stock option grant covering 123,600 shares of Class A common stock. The option was awarded on May 28, 2026 at an exercise price of $0.9515 per share and is held directly.
The option vests in full on the first anniversary of the grant date, subject to the director’s continuous service under the company’s 2021 Equity Incentive Plan. Vesting can occur earlier if Rani Therapeutics holds its next annual stockholder meeting or if a Change in Control occurs, in each case only if continuous service requirements are met. After this grant, the director holds 123,600 derivative securities related to this option.
Rani Therapeutics Holdings director Dennis A. Ausiello received a grant of stock options covering 123,600 shares of Class A common stock. The options have an exercise price of $0.9515 per share and expire on May 27, 2036. This is a compensation-related award rather than an open-market purchase.
The options vest in full on the first anniversary of the grant date, subject to Dr. Ausiello’s continuous service. Vesting can occur earlier if either the company’s next annual stockholder meeting or a Change in Control happens while he remains in continuous service. Following this grant, he holds options for 123,600 shares directly.
Rani Therapeutics Holdings, Inc. held its annual stockholder meeting on May 28, 2026. Stockholders voted together as a single class, with one vote per share of both Class A and Class B common stock. As of April 2, 2026, there were 99,812,515 Class A shares and 23,970,359 Class B shares outstanding and entitled to vote.
All seven director nominees, including Talat Imran, Mir Imran, and the other board members listed, were elected to serve until the 2027 annual meeting or until successors are elected and qualified. Stockholders also ratified the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.